Back to News
Market Impact: 0.15
Capricor To Present 24-Month HOPE-3 Data At WMS 2026
Source: Nasdaq
Healthcare & Biotech
Capricor Therapeutics will present new data from its Phase 3 HOPE-3 trial and open-label extension of deramiocel at the World Muscle Society Congress in Hiroshima, Japan, from September 29 to October 3, 2026. The announcement provides a future clinical-data catalyst but includes no efficacy, safety, regulatory, or financial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
CAPR0.20
More News
- Halozyme prices $1.3 billion convertible notes offering
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
- FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A
- Why is Xenon Pharmaceuticals stock plunging today?
- Intel and Micron lead our portfolio higher, and J&J's strengthens our case for owning it
- Ultragenyx stock surges 10% on FDA approval for gene therapy
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Options, Earnings Call Transcripts, AI Chat, Bookmarks & More
- AI Tools for Family Offices: A Stack by Decision Type